Navigation Links
Data on ElectroCore's Vagal Nerve Stimulation Therapy GammaCore Selected for an Oral Presentation at the 65th American Academy of Neurology Annual Meeting
Date:3/13/2013

MORRIS PLAINS, N.J., March 13, 2013 /PRNewswire/ -- ElectroCore®, a company dedicated to developing effective, non-invasive Vagal Nerve Stimulation (nVNS) therapies for serious medical conditions including primary headaches, announced today that data demonstrating the efficacy of its GammaCore® therapy as an acute treatment for migraine was accepted for an oral presentation at the American Academy of Neurology Annual Meeting March 16-23 in San Diego.

The open-label pilot study "Non-Invasive Neurostimulation of the Vagus Nerve with the GammaCore Device for the Relief of Symptoms Associated with Migraine" was conducted by Peter Goadsby , M.D., director of the University of California San Francisco Headache Center; Roger Cady , M.D., founder of the Headache Care Center; Brian Grosberg , M.D., director of the Montefiore Headache Center and Alexander Mauskop , founder and director of the New York Headache Center. The data will be presented on Wednesday, March 20, at 4:39 p.m. PDT in the Moderated Platform Session S40: Headache: Clinical.

"The study's results suggest GammaCore's non-invasive vagal nerve stimulation to potentially be an effective and well-tolerated acute treatment for migraine," said J.P. Errico , CEO of ElectroCore. "One-third of all patients who were treated while experiencing mild, moderate or severe pain were pain free at two hours."

In the study, 27 enrolled participants treated an acute migraine with a portable nVNS device (GammaCore). Treatment consisted of two, 90-second doses, at 15-minute intervals delivered to the right cervical branch of the vagus nerve. Two-thirds of patients treated at mild pain were pain free at two hours. Treatment related adverse effects were limited.

"We are currently enrolling our FDA-approved chronic migraine prevention study at several sites across the U.S., with an initial readout expected later this year," said Errico.  "We believe the study will further demonstrate the efficacy of GammaCore as an important new treatment option for the many Americans who suffer from migraine."

For more information about ElectroCore's AAN presentation, visit  http://www.abstracts2view.com/aan/view.php?nu=AAN13L_S40.004.

About GammaCore®
GammaCore is a non-invasive, vagus nerve stimulator that produces a mild electrical signal which is transmitted to the vagus nerve through the skin. It's indicated for the acute and/or prophylactic treatment of migraine, cluster headache, and medication overuse headache (MOH) in adults. GammaCore is currently available in the European Union, South Africa, India, New Zealand, Australia, Colombia and Malaysia for the acute and/or prophylactic treatment of migraine, cluster headache, and MOH in adults. GammaCore is available in Canada for cluster headache only.

About ElectroCore®
ElectroCore is a healthcare company focused on non-invasive neuromodulation therapies for the treatment of diseases and disorders. The company has developed non-invasive Vagal Nerve Simulation (nVNS) therapies intended to treat and/or prevent symptoms of a number of highly prevalent and disabling conditions. ElectroCore currently has three commercial products on the market: GammaCore®, AlphaCore®, and GammaCore VET™. The company is headquartered in Morris Plains, NJ, with international offices in Stockholm, Sweden, Hamilton, Bermuda, and Sydney, Australia.

For more information, visit: http://www.electrocoremedical.com/.


'/>"/>
SOURCE ElectroCore Medical
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. NeuroSigma Announces Receipt of Notice of Allowance of U.S. Patent Application Related to External Trigeminal Nerve Stimulation (eTNS) for the Treatment of Neuropsychiatric Disorders
2. Study Demonstrates Percutaneous Tibial Nerve Stimulation Offers More Cost-Effective OAB Treatment Than Sacral Nerve Stimulation
3. New Candidate Drug Stops Cancer Cells, Regenerates Nerve Cells
4. Interim Results Reported for Phase I Open-Label Clinical Trial for the Treatment of PTSD and MDD Using External Trigeminal Nerve Stimulation (eTNS™) - The USB Port to the Brain™
5. Percutaneous Tibial Nerve Stimulation Included in the American Urological Associations Overactive Bladder Clinical Treatment Guidelines
6. Results Reported for Phase Ib Open-Label Clinical Trial for the Treatment of Depression Using External Trigeminal Nerve Stimulation (eTNS™) - The USB Port to the Brain™
7. Lower Extremity Functional Electrical Stimulation Cycling Promotes Physical & Neurological Recovery in Chronic Spinal Cord Injury
8. Deep Brain Stimulation Clinic Expedites Patient Treatment at Muhammad Ali Parkinson Center
9. Analysis of the U.S. Neurostimulation Market
10. Global Neurostimulation Industry
11. Texas Childrens Hospital is first in North America to own Leica Microsystems Gated Stimulation Emission Depletion microscope
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/4/2017)... SEOUL, South Korea , Oct. 4, 2017 /PRNewswire/ ... launched its next-generation CPR training aide "cprCUBE" on Kickstarter. ... of chest compression during cardiac arrests with better efficiency ... patient-mannequins. It also offers real-time feedback on efficacy of ... The crowdfunding campaign has a goal to raise ...
(Date:10/2/2017)... Lilly and Company (NYSE: LLY ) will ... 2017 on Tuesday, October 24, 2017. Lilly will also ... investment community and media to further detail the company,s ... at 9 a.m. Eastern time. Investors, media and the ... conference call through a link that will be posted ...
(Date:9/28/2017)... CHICAGO , Sept. 28, 2017 Hill-Rom ... quarter 2017 earnings conference call and webcast on Friday, ... 8:00 a.m. (EDT) and ending at approximately 8:30 a.m. ... to discussing the company,s 2017 financial performance and guidance ... growth opportunities, initiatives to enhance operational performance, and long-range ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... Many families have long-term ... long-term care insurance companies have a waiver for care if the client has a ... when the family pays for care, is often waived, so the benefits from their ...
(Date:10/13/2017)... ... 2017 , ... Global Healthcare Management’s 4th Annual Kids Fun Run brought out ... free event, sponsored by Global Healthcare Management’s CEO, Jon Letko, is aimed at getting ... children of all ages; it is a non-competitive, non-timed event, which is all about ...
(Date:10/13/2017)... , ... October 13, 2017 , ... ... and Agile Software Development, has been awarded a contract by the Center for ... Agreement (BPA) aims to accelerate the enterprise use of Agile methodologies in a ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... healthcare compliance program management, will showcase a range of technology and learning solutions ... Living (NCAL) Convention and Expo to be held October 14–18, 2017 at the ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company ... of today’s consumer and regulatory authorities worldwide. From Children’s to Adults 50+, every ... meet the highest standard. , These products are also: Gluten Free, Non-GMO, ...
Breaking Medicine News(10 mins):